Annovis Bio Inc. Webcast FAQ: Updates on Alzheimer’s and Parkinson’s Programs

What is the purpose of the Annovis Bio Inc. webcast?

The webcast aims to provide updates on Annovis Bio’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives, followed by a live Q&A session.

When and where will the Annovis Bio Inc. webcast take place?

The webcast is scheduled for June 24, 2025, at 4:30 PM EDT and will be hosted online, accessible to shareholders, patients, and other stakeholders.

Who will be speaking at the Annovis Bio Inc. webcast?

Maria Maccecchini, Ph.D., President and CEO of Annovis Bio, will be the featured speaker during the webcast.

How can I access the Annovis Bio Inc. webcast?

Details on how to access the webcast can be found in the full press release available at https://ibn.fm/aWfFp.

What is Annovis Bio Inc. focused on?

Annovis Bio is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s by developing innovative therapies that target multiple neurotoxic proteins to restore brain function and improve patients’ quality of life.

Where can I find more information about Annovis Bio Inc.?

For more information, visit the company’s website at www.AnnovisBio.com, and their social channels on LinkedIn, X, and YouTube.

What are the latest updates available for ANVS?

The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.

What is BioMedWire?

BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, providing access to a vast network of wire solutions and enhanced press release services.